Angiogenesis inhibitors for metastatic colorectal cancer
- PMID: 38192992
- PMCID: PMC10774035
- DOI: 10.21037/tcr-23-1568
Angiogenesis inhibitors for metastatic colorectal cancer
Keywords: Colorectal cancer (CRC); angiogenesis inhibitors; fruquintinib.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1568/coif). The authors have no conflicts of interest to declare.
Comment on
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15. Lancet. 2023. PMID: 37331369 Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources